Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator‐Initiated Randomized, Open‐Label, Non‐Inferiority Trial

Pediatric Blood & Cancer 2026

View at publisher
Authors: Azgar Abdul Rasheed, Shuvadeep Ganguly, Manraj Singh, Santhosh E. Kumar, Atul Batra, Deepam Pushpam, Sreenivas Vishnubhatla, Ashwati S. Pillai, Anu Theresa Joison, Swetambri Sharma, Sameer Bakhshi
DOI: 10.1002/1545-5017.70171
Cited by: 2
References: 24

Abstract

BACKGROUND: Fosaprepitant is non-inferior to aprepitant in adults receiving highly emetogenic chemotherapy (HEC). We evaluated whether fosaprepitant is non-inferior to aprepitant in children receiving HEC. METHODS: In this open-label, non-inferiority trial, children aged 5-18 years, receiving their first cycle of HEC, were randomized 1:1 to the fosaprepitant or aprepitant group. The fosaprepitant group received a single intravenous dose of 4 mg/kg (max 150 mg). The aprepitant group received oral aprepitant capsules (weight 15 to

Fields of Study & Subjects

Nausea and vomiting management Anesthesia and Neurotoxicity Research Cancer Stress Anesthesia and Immune Response

Publication details

Journal / source
Pediatric Blood & Cancer
Publisher
Wiley
Volume
73
Issue
5
Pages
e70171–e70171
Publication date
13 March 2026
Language
EN